Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-06-25
2003-06-17
Siew, Jeffrey (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200
Reexamination Certificate
active
06579855
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the treatment of brain tumours using gene therapy.
BACKGROUND OF THE INVENTION
The treatment of malignant glioma continues to challenge physicians and scientists. Thymidine kinase gene therapy, using the Herpes Simplex virus thymidine kinase (HSVtk) gene, is one of the most promising treatment modalities, in attempts to change the survival of malignant glioma patients. HSVtk gene therapy is based on the ability of thymidine kinase to catalyze the phosphorylation of ganciclovir (GCV). Phosphorylated GCV acts as a toxic nucleotide analogue, leading to the death of the target cells. This phenomenon is further enhanced by a bystander effect, where neighbouring cells are also destroyed even without transfection. This effect is thought to be due to the release of toxic nucleotide analogues from the transfected cells to neighbouring cells via gap junctions.
Retroviruses and adenoviruses have been used as vectors for gene therapy. Both vectors have certain advantages and limitations. Brain tumours are especially suitable for retrovirus-mediated gene transfer, since retroviruses can only infect proliferating cells while normal, non-dividing brain tissue remains intact. The gene transfer efficiency of retroviruses is relatively low, but could be improved by using retrovirus packaging cells instead of isolated viruses. The transduction time can theoretically be prolonged and the number of transfected cells increased. With retroviruses, the transfected gene incorporates into the genome of the target cell and therefore long-term gene expression can be achieved.
SUMMARY OF THE INVENTION
The present invention is based on the surprising finding that treatment of brain tumours using thymidine kinase gene therapy can be accomplished more effectively if an adenovirus is used as the vehicle to transfer the gene into tumour cells.
According to the present invention, an adenovirus comprises a gene encoding thymidine kinase, and medicaments containing it, are useful for treating a brain tumour. In particular, the tumour is treated following administration of gangciclovir or an equivalent compound.
The thymidine kinase gene will typically be that derived from the Herpes Simplex virus (HSVtk).
The adenovirus/thymidine kinase gene construct is shown to be more beneficial than retrovirus gene transfer.
DESCRIPTION OF THE INVENTION
A construct of the invention can be used to treat a tumour. Treatment may comprise the steps of:
(i) administering an adenovirus comprising a gene encoding a thymidine kinase, into the wall of the tumour cavity; and
(ii) administering a compound that forms a cytotoxic compound when phosphorylated.
The compound used in step (ii) may be ganciclovir or a derivative thereof. This method may be used to treat any tumour, preferably a brain tumour, e.g. a malignant glioma. The composition used in step (i) may be administered repeatedly, preferably in 40 to 80 separate applications.
The composition used in the present invention is preferably formulated without the addition of proteins (other than those associated with the adenovirus). This is believed to be preferable to those compositions where albumin is added to reduce the effects of degradative enzymes on the active components. Preferably, this composition comprises glycerol as a stabiliser.
The amount of active products that should be administered to a patient, in use of the invention, can be determined by those skilled in the art, based on information provided herein and on the usual considerations such as the route of administration, the condition being treated and its status, etc.
The following Example illustrates the invention.
REFERENCES:
patent: 5631236 (1997-05-01), Woo et al.
patent: 6066624 (2000-05-01), Woo et al.
patent: 6217860 (2001-04-01), Woo et al.
Averett et.al.; 6-Methoxypurine Arabinoside as a Selective and Potent Inhibitor of Varicella-Zoster Virus, 1991, Antimicrobial Agents and Chemotherapy: 851-857.*
Ross et.al.; Assessment of Ganciclovir Toxicity to experimental Intracranial Gliomas following Recombinant Adenoviral-mediated . . . Kinase Gene by Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy, 1995, Clinical Cancer Research, vol. 1: 651-657.*
Eck et.al.; Treatment of Advanced CNS Malignancies with the Recombinant Adenovirus H5.010RSVTK: A Phase I Trial, 1996, Human Gene Therapy 7: 1465-1482.*
Verma et.al.; Gene therapy-promises, problems and prospects, 1997, Nature: 239-242.*
Miller et.al.; Targeted vectors for gene therapy, 1995, FASEB J. 9: 190-199.*
Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin.Ther. Patents 8: 53-69.*
Crystal, Transfer of Genes to Human: Early Lessons and Obstacles to Success, 1995, Science, vol. 270: 404-410.*
Perez-Cruet, M.J. et al. (Nov. 1, 1994) “Adenovirus-Mediated Gene Therapy of Experimental Glomas”Journal of Neuroscience Research39(4):506-511 (US, Wiley-Liss).
Chen Shu-Hsia et al. (1994) “Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo”Proceedings of the National Academy of Sciences of the United States of America91(8):3054-3057.
Maron, A. et al. (1996) “Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: Long-term follow-up by magnetic resonance imaging”Gene Therapy3(4):315-322.
Driesse, M. J. et al. (Aug. 1998) “Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: Toxicity study in nonhuman primates”Gene Therapy5(8):1122-1129.
Loimas Sami
Sandmair Anu-Maaria
Vapalahti Matti
Yla-Herttuala Seppo
Ark Therapeutics Ltd.
Schnizer Richard
Siew Jeffrey
LandOfFree
Adenovirus-mediated gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenovirus-mediated gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus-mediated gene therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3113495